U.S. markets open in 4 hours 10 minutes
  • S&P Futures

    3,788.75
    +26.50 (+0.70%)
     
  • Dow Futures

    30,887.00
    +167.00 (+0.54%)
     
  • Nasdaq Futures

    12,929.50
    +127.25 (+0.99%)
     
  • Russell 2000 Futures

    2,147.60
    +26.80 (+1.26%)
     
  • Crude Oil

    52.56
    +0.20 (+0.38%)
     
  • Gold

    1,842.10
    +12.20 (+0.67%)
     
  • Silver

    25.41
    +0.54 (+2.19%)
     
  • EUR/USD

    1.2130
    +0.0047 (+0.39%)
     
  • 10-Yr Bond

    1.0970
    0.0000 (0.00%)
     
  • Vix

    22.87
    -0.38 (-1.63%)
     
  • GBP/USD

    1.3622
    +0.0036 (+0.26%)
     
  • USD/JPY

    103.9920
    +0.3050 (+0.29%)
     
  • BTC-USD

    37,263.36
    +821.62 (+2.25%)
     
  • CMC Crypto 200

    735.74
    +0.60 (+0.08%)
     
  • FTSE 100

    6,736.32
    +15.67 (+0.23%)
     
  • Nikkei 225

    28,633.46
    +391.25 (+1.39%)
     

Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12

RP Management, LLC
·1 min read

NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. EST.

Investors, analysts, members of the media and the general public are invited to listen to a live webcast of the presentation at https://www.royaltypharma.com/investors/news-and-events/events. A replay of the webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko, Orkambi and Trikafta, and four development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-2295
ir@royaltypharma.com